MTHFR Gene Mutations: A Potential Marker of Late-Onset Alzheimer's Disease?

Area of Science:

• Neuroscience
• Genetics
• Epigenetics

Background:

• Epigenetic modifications, particularly DNA methylation, are increasingly recognized in late-onset Alzheimer's disease (LOAD).
• Metabolic folate pathways and B-group vitamins are crucial for methyl donor reactions, potentially influencing LOAD pathogenesis.

Purpose of the Study:

• To investigate the prevalence of methylenetetrahydrofolate reductase (MTHFR) gene mutations in patients with late-onset Alzheimer's disease.
• To explore the potential of MTHFR mutations as a biomarker for LOAD.

Main Methods:

• DNA analyses were performed on 93 consecutive elderly patients diagnosed with Alzheimer's disease.
• Specific MTHFR gene polymorphisms, MTHFR-C667T and -A1298C (both homozygous and heterozygous), were analyzed.

Main Results:

• A high prevalence of MTHFR mutations was observed in the patient cohort, with 92.5% of individuals exhibiting these polymorphisms.
• The study identified significant MTHFR gene mutations in elderly patients with LOAD.

Conclusions:

• MTHFR gene mutations are highly prevalent in patients with late-onset Alzheimer's disease.
• These mutations may represent a potential diagnostic marker for LOAD.
• Further research with larger patient cohorts is needed to confirm these findings and explore therapeutic implications.